Drugs / TAC01-HER2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04727151 | Apr 2021 → Dec 2023 | gastroesophageal cancer | Triumvira Immunologics, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-04-17 | Triumvira Immunologics, Inc. | Results Patient-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform is highly functional in models of solid tumors triumvira.com ↗ |
| 2023-03-19 | Triumvira Immunologics, Inc. | Results Triumvira Immunologics to Present New Data on its TAC T Cell Autologous and Allogeneic Products and the Ongoing Phase I/II Solid Tumor Trial at the 2023 AACR Annual Meeting triumvira.com ↗
Interim results will also be presented from our ongoing Phase I/II trial investigating the safety and efficacy of autologous TAC01-HER2 in HER2+ refractory solid tumors demonstrating a favorable safety profile |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-05-16 | Triumvira Immunologics, Inc. | Triumvira Immunologics to Present Clinical Data from Phase I/II Trial TACTIC-2 Investigating TAC01-HER2 at the 2023 ASCO Annual Meeting triumvira.com ↗ |
| 2023-04-17 | Triumvira Immunologics, Inc. | Patient-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform is highly functional in models of solid tumors triumvira.com ↗ |
| 2023-03-19 | Triumvira Immunologics, Inc. | Triumvira Immunologics to Present New Data on its TAC T Cell Autologous and Allogeneic Products and the Ongoing Phase I/II Solid Tumor Trial at the 2023 AACR Annual Meeting triumvira.com ↗ |
| 2023-01-06 | Triumvira Immunologics, Inc. | Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors triumvira.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAC01-HER2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04727151 ↗ |
| Action | Deplete | “TAC T cells recognize the HER2 protein present on the surface of tumor cells, and eradicate them.” NCT04727151 ↗ |
| Modality | Cell therapy | “TAC01-HER2 is a novel cell therapy” NCT04727151 ↗ |
| Route | Intravenous | “Lymphodepletion followed by TAC01-HER2 as a single IV infusion” NCT04727151 ↗ |